Name: Generation of Induced Pluripotent Stem Cells from Human Peripheral T Cells Using Sendai Virus in Feeder-free Conditions (Video) | JoVE Journal
Uploaded: 2015-11-11T15:00:00.000+00:00
Duration: 9 min 32 s
Description: Learn to generate induced pluripotent stem cells from human peripheral T cells using Sendai virus vectors in feeder-free conditions. This method enables safe clinical applications in regenerative medicine.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

We thank Yoshiko Miyake, Sayaka Kanaami, Chihana Fujita, Miho Yamaguchi, Natsuko Henmi, and Rei Ohno from the Keio University School of Medicine for technical assistance. This work was partly funded by an R&#38;D Systems support program to accelerate the practical use of health research outcomes, and the Highway Program for the Realization of Regenerative Medicine.

1. Prepare Activated Human T Cells
<ol>
	<li>Collect 10 ml heparinized whole blood from a donor by venipuncture.
	<ol>
		<li>Obtain informed consent of donors in advance of venipuncture. Venipuncture must be done by qualified and trained personnel.</li>
		<li>Handle obtained blood samples with sterile equipment and following appropriate biosafety guidelines.</li>
	</ol>
	</li>
	<li>Dilute 10 ml heparinized whole blood with 10 ml D-PBS(&#8211;).</li>
	<li>Put 15 ml Ficoll solution (Ficoll-Paque PREMIUM) into a new 50-ml conical tube.</li>
	<li>Layer the 20-ml blood solution prepared in Step 1.2 onto the Ficoll solution in Step 1.3. Using an electric pipette, let blood solution prepared in Step 1.2 run slowly along the inside wall of tube. Be careful not to mix the blood solution and Ficoll solution.</li>
	<li>Centrifuge at 400 &#215; g for 30 min at RT. Set the centrifugal deceleration speed to &#8220;slow&#8221;. 
	Note: After centrifugation, a white thin layer emerges between an upper milky plasma layer and a lower clear Ficoll layer. This white thin layer contains mononuclear cells.</li>
	<li>Transfer the mononuclear cell layer to a new 50-ml conical tube with a 1-ml pipette. Be careful not to include Ficoll solution.</li>
	<li>Add D-PBS(&#8211;) to the mononuclear cells to a total volume of 10 ml, and centrifuge at 200 &#215; g for 5 min at RT.</li>
	<li>Discard the supernatant. Add 10 ml of D-PBS(&#8211;) to the mononuclear cells, and centrifuge at 200 &#215; g for 5 min at RT.</li>
	<li>Discard the supernatant, add 1 ml of KBM502 medium to the collected mononuclear cells, and count the cells using a hemocytometer. Over 5 &#215; 106 mononuclear cells can be obtained from 10 ml heparinized whole blood with appropriate separation using Ficoll.</li>
	<li>Prepare an anti-human CD3 antibody solution at a concentration of 10 &#181;g/ml in D-PBS(&#8211;). Add the anti-human CD3 antibody solution to a 6-well plate, soak the surface of each well, and incubate the dish at 37 &#176;C in a 5% CO2 incubator for at least 30 min.</li>
	<li>Remove the anti-human CD3 antibody solution from each well and wash once with D-PBS(&#8211;) just prior to seeding the cells.</li>
	<li>Seed mononuclear cells that were prepared in Step 1.9 at a density of 2.5 &#215; 105 cells/cm2 on the anti-human CD3 antibody-coated 6-well plates in KBM502 medium. Incubate at 37 &#176;C in a 5%-CO2 incubator for 3&#8211;7 days without medium change until the T cells reach confluency. T cells in this period are both suspended and adhering cells.</li>
</ol>
2. Infect Human T Cells with SeV Vectors
<ol>
	<li>After 3&#8211;7 days culture, collect the activated T cells with existing medium by pipetting. Transfer them to a 15-ml conical tube and centrifuge at 200 &#215; g for 5 min at RT.</li>
	<li>Remove the supernatant and add 1 ml fresh KBM502 medium. Count the cells and plate 1.5 &#215; 106 cells (in 2 ml fresh KBM502 medium) into each well of an anti-CD3 antibody-coated 6-well plate.</li>
	<li>Thaw the SeV solutions of OCT3/4-SeV/TS&#916;F, SOX2-SeV/TS&#916;F, KLF4-SeV/TS&#916;F, and c-MYC (HNL)-SeV/TS15&#916;F on ice.</li>
	<li>Add the SeV solutions containing OCT3/4-SeV/TS&#916;F, SOX2-SeV/TS&#916;F, KLF4-SeV/TS&#916;F, and c-MYC (HNL)-SeV/TS15&#916;F individually to the wells, each at a multiplicity of infection (MOI) of 10. Incubate at 37 &#176;C in a 5%-CO2 incubator for a further 24 hr.</li>
</ol>
3. Remove SeV Vectors from Human T Cells
<ol>
	<li>24 hr after infection, collect the infected cells with a pipette. If there are adhering cells, they can easily be detached pipetting them repeatedly up and down. Transfer them to a 15-ml conical tube, and centrifuge at 200 &#215; g for 5 min at RT.</li>
	<li>Remove the supernatant containing the SeV vectors, and add 2 ml fresh KBM502 medium. Replate cells in each of the wells. Incubate at 37 &#176;C in a 5%-CO2 incubator for an additional 24 hr.</li>
</ol>
4. Reseed Cells on a Matrigel Layer
<ol>
	<li>Prepare basement membrane matrix solution by thawing matrix gel (please see the Materials List for the specific brand used in this study) at 4 &#176;C and dissolving 0.2 ml in 10 ml of DMEM/F12 medium. 
	Note: Matrix gel (please see the Materials List for the specific brand used in this study) needs to thaw O/N at 4 &#176;C to be completely thawed. Keep it on ice until just before use.</li>
	<li>Plate 5 ml basement membrane matrix solution per dish into 100-mm dishes and leave at RT for at least 30 min before seeding cells. At least two 100-mm dishes are needed for one experiment.</li>
	<li>Collect SeV-infected cells by pipetting, transfer them to a 15-ml conical tube, and centrifuge at 200 &#215; g for 5 min at RT.</li>
	<li>Remove the supernatant and add 1 ml fresh KBM502 medium. Count the number of cells using a hemocytometer, remove the basement membrane matrix solution from 100-mm dishes prepared in Step 4.2 and plate 1 &#215; 105 and 1 &#215; 106 cells (in 10 ml fresh mTeSR medium) on a 100-mm basement membrane matrix-coated dishes. Finally, use the plate in which colonies are easily picked.</li>
	<li>Incubate the dish at 37 &#176;C in a 5%-CO2 incubator O/N.</li>
	<li>Change the medium to 10 ml flesh mTeSR medium every other day. 
	Note: Approximately 20&#8211;30 days after infection, colonies that closely resemble embryonic stem cells (ESCs) will appear.</li>
</ol>
5. Expand T Cell-derived iPSCs
<ol>
	<li>Prepare basement membrane matrix solution by thawing matrix gel (please see the Materials List for the specific brand used in this study) at 4 &#176;C and dissolving 0.2 ml in 10 ml of DMEM/F12 medium.</li>
	<li>Plate 1 ml of the basement membrane matrix solution per well in a 6-well plate and leave at RT for at least 30 min before picking colonies.</li>
	<li>Fill a 96-well plate with 20 &#181;l of mTeSR medium per well.</li>
	<li>Select colonies that resemble ESCs under the stereomicroscope using a 20 &#181;l pipette. 
	Note: The colonies of ESCs and iPSCs are round and flat as shown in Figure 1B.</li>
	<li>Transfer selected colonies into the 96-well plate filled with mTeSR medium in Step 5.3.</li>
	<li>Add 200 &#181;l of mTeSR medium to each well and carefully pipette up and down to break the colony into small clumps under the stereomicroscope using a 200 &#181;l pipette. Remove the basement membrane matrix solution from the well prepared in 5.2 and put each colony into one well of the basement membrane matrix-coated 6-well plate with 2 ml of mTeSR medium per well.</li>
	<li>Change the medium to 2 ml flesh mTeSR medium every other day.</li>
</ol>
6. Maintain T Cell-derived iPSCs
The T cell-derived iPSCs can be maintained and stored using the same techniques as for human iPSCs and human ESCs. Once iPSC colonies grow up, expand them into larger dishes by repeating the same procedure.
<ol>
	<li>Change the mTeSR medium every 1&#8211;2 days.</li>
	<li>When the colonies become confluent every 5&#8211;7 days, passage the cells using dissociation solution for human iPSCs and human ESCs according to the manufacturer&#8217;s instructions.</li>
</ol>

<ol><li>Takahashi, K., Yamanaka, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Induction+of+pluripotent+stem+cells+from+mouse+embryonic+and+adult+fibroblast+cultures+by+defined+factors%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.</a> Cell. 126, 663-676 (2006).</li>
<li>Takahashi, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Induction+of+pluripotent+stem+cells+from+adult+human+fibroblasts+by+defined+factors%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Induction of pluripotent stem cells from adult human fibroblasts by defined factors.</a> Cell. 131, 861-872 (2007).</li>
<li>Yu, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Induced+pluripotent+stem+cell+lines+derived+from+human+somatic+cells%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Induced pluripotent stem cell lines derived from human somatic cells.</a> Science. 318 (5858), 1917-1920 (2007).</li>
<li>Hayes, M., Zavazava, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Strategies+to+generate+induced+pluripotent+stem+cells%5BTitle%5D)+AND+%22Methods+Mol+Biol%22%5BJournal%5D)">Strategies to generate induced pluripotent stem cells.</a> Methods Mol Biol. 1029, 77-92 (2013).</li>
<li>Gonzalez, F., Boue, S., Izpisua Belmonte, J. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Methods+for+making+induced+pluripotent+stem+cells%3A+reprogramming+a+la+carte%5BTitle%5D)+AND+%22Nat+Rev+Genet%22%5BJournal%5D)">Methods for making induced pluripotent stem cells: reprogramming a la carte.</a> Nat Rev Genet. 12, 231-242 (2011).</li>
<li>Loh, Y. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Reprogramming+of+T+cells+from+human+peripheral+blood%5BTitle%5D)+AND+%22Cell+Stem+Cell%22%5BJournal%5D)">Reprogramming of T cells from human peripheral blood.</a> Cell Stem Cell. 7, 15-19 (2010).</li>
<li>Seki, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Generation+of+induced+pluripotent+stem+cells+from+human+terminally+differentiated+circulating+T+cells%5BTitle%5D)+AND+%22Cell+Stem+Cell%22%5BJournal%5D)">Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells.</a> Cell Stem Cell. 7, 11-14 (2010).</li>
<li>Staerk, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Reprogramming+of+human+peripheral+blood+cells+to+induced+pluripotent+stem+cells%5BTitle%5D)+AND+%22Cell+Stem+Cell%22%5BJournal%5D)">Reprogramming of human peripheral blood cells to induced pluripotent stem cells.</a> Cell Stem Cell. 7, 20-24 (2010).</li>
<li>Nishimura, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Generation+of+rejuvenated+antigen-specific+T+cells+by+reprogramming+to+pluripotency+and+redifferentiation%5BTitle%5D)+AND+%22Cell+Stem+Cell%22%5BJournal%5D)">Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation.</a> Cell Stem Cell. 12, 114-126 (2013).</li>
<li>Vizcardo, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Regeneration+of+Human+Tumor+Antigen-Specific+T+Cells+from+iPSCs+Derived+from+Mature+CD8+T+Cells%5BTitle%5D)+AND+%22Cell+Stem+Cell%22%5BJournal%5D)">Regeneration of Human Tumor Antigen-Specific T Cells from iPSCs Derived from Mature CD8 T Cells.</a> Cell Stem Cell. 12, 31-36 (2013).</li>
<li>Sampsell-Barron, T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Xeno-free+adaptation+and+culture+of+human+pluripotent+stem+cells%5BTitle%5D)+AND+%22Methods+Mol+Biol%22%5BJournal%5D)">Xeno-free adaptation and culture of human pluripotent stem cells.</a> Methods Mol Biol. 1001, 81-97 (2013).</li>
<li>Thomson, J. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Embryonic+stem+cell+lines+derived+from+human+blastocysts%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Embryonic stem cell lines derived from human blastocysts.</a> Science. 282, 1145-1147 (1998).</li>
<li>Minegishi, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Enhanced+optineurin+E50K-TBK1+interaction+evokes+protein+insolubility+and+initiates+familial+primary+open-angle+glaucoma%5BTitle%5D)+AND+%22Hum+Mol+Genet%22%5BJournal%5D)">Enhanced optineurin E50K-TBK1 interaction evokes protein insolubility and initiates familial primary open-angle glaucoma.</a> Hum Mol Genet. 22, 3559-353367 (2013).</li>
<li>Tanaka, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Endothelin-1+induces+myofibrillar+disarray+and+contractile+vector+variability+in+hypertrophic+cardiomyopathy-induced+pluripotent+stem+cell-derived+cardiomyocytes%5BTitle%5D)+AND+%22J+Am+Heart+Assoc%22%5BJournal%5D)">Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes.</a> J Am Heart Assoc. 3, e001263(2014).</li>
<li>Ludwig, T. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Derivation+of+human+embryonic+stem+cells+in+defined+conditions%5BTitle%5D)+AND+%22Nat+Biotechnol%22%5BJournal%5D)">Derivation of human embryonic stem cells in defined conditions.</a> Nat Biotechnol. 24, 185-187 (2006).</li>
<li>Kishino, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Derivation+of+transgene-free+human+induced+pluripotent+stem+cells+from+human+peripheral+T+cells+in+defined+culture+conditions%5BTitle%5D)+AND+%22PLoS+One%22%5BJournal%5D)">Derivation of transgene-free human induced pluripotent stem cells from human peripheral T cells in defined culture conditions.</a> PLoS One. 9, e97397(2014).</li>
<li>Masaki, I., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Recombinant+Sendai+virus-mediated+gene+transfer+to+vasculature%3A+a+new+class+of+efficient+gene+transfer+vector+to+the+vascular+system%5BTitle%5D)+AND+%22FASEB+J%22%5BJournal%5D)">Recombinant Sendai virus-mediated gene transfer to vasculature: a new class of efficient gene transfer vector to the vascular system.</a> FASEB J. 15, 1294-1296 (2001).</li>
<li>Li, H. O., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+cytoplasmic+RNA+vector+derived+from+nontransmissible+Sendai+virus+with+efficient+gene+transfer+and+expression%5BTitle%5D)+AND+%22J+Virol%22%5BJournal%5D)">A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression.</a> J Virol. 74, 6564-6569 (2000).</li>
<li>Ikeda, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Recombinant+Sendai+virus-mediated+gene+transfer+into+adult+rat+retinal+tissue%3A+efficient+gene+transfer+by+brief+exposure%5BTitle%5D)+AND+%22Exp+Eye+Res%22%5BJournal%5D)">Recombinant Sendai virus-mediated gene transfer into adult rat retinal tissue: efficient gene transfer by brief exposure.</a> Exp Eye Res. 75, 39-48 (2002).</li>
<li>Fusaki, N., Ban, H., Nishiyama, A., Saeki, K., Hasegawa, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Efficient+induction+of+transgene-free+human+pluripotent+stem+cells+using+a+vector+based+on+Sendai+virus%2C+an+RNA+virus+that+does+not+integrate+into+the+host+genome%5BTitle%5D)+AND+%22Proc+Jpn+Acad+Ser+B+Phys+Biol+Sci%22%5BJournal%5D)">Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome.</a> Proc Jpn Acad Ser B Phys Biol Sci. 85, 348-362 (2009).</li>
<li>Macarthur, C. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Generation+of+human-induced+pluripotent+stem+cells+by+a+nonintegrating+RNA+Sendai+virus+vector+in+feeder-free+or+xeno-free+conditions%5BTitle%5D)+AND+%22Stem+cells+Int%22%5BJournal%5D)">Generation of human-induced pluripotent stem cells by a nonintegrating RNA Sendai virus vector in feeder-free or xeno-free conditions.</a> Stem cells Int. , 564612(2012).</li>
<li>Iida, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Sendai+virus+vector%3A+vector+development+and+its+application+to+health+care+and+biotechnology%5BTitle%5D)+AND+%22Uirusu%22%5BJournal%5D)">Sendai virus vector: vector development and its application to health care and biotechnology.</a> Uirusu. 57, 29-36 (2007).</li>
<li>Yoshida, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((In+vivo+repopulation+of+cytoplasmically+gene+transferred+hematopoietic+cells+by+temperature-sensitive+mutant+of+recombinant+Sendai+viral+vector%5BTitle%5D)+AND+%22Biochem+Biophys+Res+Comm%22%5BJournal%5D)">In vivo repopulation of cytoplasmically gene transferred hematopoietic cells by temperature-sensitive mutant of recombinant Sendai viral vector.</a> Biochem Biophys Res Comm. 361, 811-816 (2007).</li>
<li>Bitzer, M., Armeanu, S., Lauer, U. M., Neubert, W. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Sendai+virus+vectors+as+an+emerging+negative-strand+RNA+viral+vector+system%5BTitle%5D)+AND+%22J+Gene+Med%22%5BJournal%5D)">Sendai virus vectors as an emerging negative-strand RNA viral vector system.</a> J Gene Med. 5, 543-553 (2003).</li>
<li>Seki, T., Yuasa, S., Fukuda, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Generation+of+induced+pluripotent+stem+cells+from+a+small+amount+of+human+peripheral+blood+using+a+combination+of+activated+T+cells+and+Sendai+virus%5BTitle%5D)+AND+%22Nat+Protoc%22%5BJournal%5D)">Generation of induced pluripotent stem cells from a small amount of human peripheral blood using a combination of activated T cells and Sendai virus.</a> Nat Protoc. 7, 718-728 (2012).</li>
<li>Okano, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Recombinant+Sendai+virus+vectors+for+activated+T+lymphocytes%5BTitle%5D)+AND+%22Gene+Ther%22%5BJournal%5D)">Recombinant Sendai virus vectors for activated T lymphocytes.</a> Gene Ther. 10, 1381-1391 (2003).</li>
<li>Okita, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((An+efficient+nonviral+method+to+generate+integration-free+human-induced+pluripotent+stem+cells+from+cord+blood+and+peripheral+blood+cells%5BTitle%5D)+AND+%22Stem+Cells%22%5BJournal%5D)">An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells.</a> Stem Cells. 31 (3), 458-466 (2013).</li>
<li>Zhang, X. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cellular+reprogramming+of+human+peripheral+blood+cells%5BTitle%5D)+AND+%22Genom+Proteom+Bioinform%22%5BJournal%5D)">Cellular reprogramming of human peripheral blood cells.</a> Genom Proteom Bioinform. 11 (5), 264-274 (2013).</li>
<li>Su, R. J., Neises, A., Zhang, X. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Generation+of+iPS+Cells+from+Human+Peripheral+Blood+Mononuclear+Cells+Using+Episomal+Vectors%5BTitle%5D)+AND+%22Methods+Mol+Biol%22%5BJournal%5D)">Generation of iPS Cells from Human Peripheral Blood Mononuclear Cells Using Episomal Vectors.</a> Methods Mol Biol. , (2014).</li>
</ol>

The authors have no competing or conflicting interests to disclose.

We describe a protocol for generating iPSCs from human peripheral T cells in serum-free and feeder-free conditions using a combination of matrigel, mTeSR medium, and SeV vectors. For clinical applications of iPSCs, it is important to have a protocol for stably generating iPSCs and a less-invasive method for cell sampling. Although generating iPSCs with the combination of matrigel and mTeSR medium showed lower reprogramming efficiency than that with knockout serum replacement (KSR) medium and feeder-cells, this combination achieves stable generation of iPSCs from donors16. Stable iPSC generation and less-invasive cell sampling has the advantage of being able to increase the number of donors for iPSC generation. 
SeV vectors, a minus-strand RNA virus, is not integrated into the host genome. Therefore the risks of tumorigenesis can be avoided at the step of reprogramming factor induction20-24. Additionally, the feeder-free conditions, which use a combination of defined culture medium and matrigel instead of a feeder layer, make it possible to minimize the potential risks of exposure to unknown exogenous factors. The fusion of these techniques provides a less invasive and safer iPSC technology for regenerative medicine16.
Important steps in this protocol are the step of activating human T cells (Step 1) and infecting them with SeV vectors (Step 2). When no ESC-like colony is obtained in the culture dish at an optimal time after SeV infection, the following should be considered. First, the confluency of the mononuclear cells before T cell activation may not be appropriate because optimal activation of T cells is critical for SeV infection25,26. Too high a density of mononuclear cells leads to cell death, interfering with the proper activation of T cells. Too low a density of mononuclear cells also disturbs the proper activation and proliferation of T cells. Therefore, the confluency of mononuclear cells should be checked and adjusted accordingly. Second, the dosage of SeV vectors may not be sufficient. The induction efficiency of iPSC colonies depends on the dosage of the virus6. If no ESC-like colony is observed after SeV infection, the option of increasing the virus dosage up to an MOI of 15-20 should be considered. If signs of iPSC colony differentiation are observed, the frequency at which medium is changed may be increased up to every other day, or to every day when colonies are larger. 
The limitation in this protocol consists of this method not being virus free. Although SeV for cell reprogramming is commercially available with ease, users need to prepare equipment according to the appropriate biosafety level. As another method for generating integration-free iPSCs, episomal vectors have been used until now27-29. Although episomal vectors can be used with equipment with a lower level of biosafety, episomal vectors might insert into the host genome at extremely low rates. Therefore, additional checks are required to confirm the disappearance of transgenes, as when using SeV.
There is another limitation in that this technique is not absolutely free from animal-derived products. Some substrates, such as matrigel, anti-CD3 mAb, dissociation solution and SeV solution are derived from animal products and are therefore associated with a risk of transferring xenogeneic pathogens. However, the reduction of animal-derived substrates in the culture system is meaningful for the clinical application of iPSC technology due to the lower risk.

iPSCs have attracted considerable attention as a groundbreaking source of cells for regenerative medicine1-3. To date, diverse methods for generating iPSCs have been reported4,5. Among these, iPSCs generated from human T cells have been of particular interest because of the less-invasive method of cell sampling6-8. Additionally, iPSCs derived from T cells contain rearrangements of the T cell receptor (TCR) gene and are thus a source of antigen-specific T cells9,10. Therefore, generating T cell derived iPSCs safely is useful for progressing regenerative medicine.
This method is based on the concept of reducing the risk of unpredictable pathogenicity. For safe clinical application of iPSCs it is important to reduce the risk of exposure to pathogens11. Previously in many culture systems of pluripotent stem cells, fetal bovine serum and feeder cells have been used as essential reagents12. However, removal of both these reagents from the culture system is preferable for iPSC generation to reduce the risk of unpredictable pathogenicity.
Additionally, this method has the advantage of avoiding invasive cell sampling from patients and laborious preparation of feeder cells. Because T cell derived iPSCs have already been used successfully in disease research13,14, this method is also applicable and useful for generating disease-specific iPSCs from patients.
Among T cell reprogramming methods, using the Sendai virus (SeV) vector as a gene vehicle is a method that can generate iPSCs with high efficiency7,16. Additionally, because SeV is a single-stranded RNA virus and does not need a DNA phase for replication, its use in iPSC generation avoids breaking the host genome17-19. Therefore, we have established protocols for generating iPSCs from human peripheral T cells in serum-free and feeder-free conditions using a combination of matrigel, mTeSR medium, and SeV vectors.

<table><tbody><tr><td>Ficoll-Paque PREMIUM</td><td>GE Healthcare</td><td>17-5442-02</td><td></td></tr><tr><td>Purified NA/LE mouse anti-human CD3</td><td>BD Pharmingen</td><td>555336</td><td></td></tr><tr><td>Bovine albumin fraction V solution</td><td>Gibco</td><td>15260-037</td><td></td></tr><tr><td>mTeSR1 medium kit</td><td>STEM CELL</td><td>5850</td><td>Warm at room temperature before use</td></tr><tr><td>Dissociation Solution</td><td>ReproCELL</td><td>RCHETP002</td><td></td></tr><tr><td>D-PBS(&amp;ndash;)</td><td>Wako</td><td>045-29795</td><td></td></tr><tr><td>SeV Vector kit CytoTune-iPS ver.1.0</td><td>DNAVEC</td><td>DV-0303c</td><td>Thaw on ice before use</td></tr><tr><td>100-mm tissue culture dish</td><td>Falcon</td><td>353003</td><td></td></tr><tr><td>96-well tissue culture plate</td><td>Falcon</td><td>353078</td><td></td></tr><tr><td>6-well tissue culture plate</td><td>Falcon</td><td>353046</td><td></td></tr><tr><td>15&amp;#160;ml Centrifuge Tube</td><td>Greiner Bio-One</td><td>188271</td><td></td></tr><tr><td>50&amp;#160;ml Centrifuge Tube</td><td>Greiner Bio-One</td><td>227261</td><td></td></tr></tbody></table>

generation of induced pluripotent stem cells from human peripheral t cells using sendai virus in feeder-free conditions

Generation of Induced Pluripotent Stem Cells from Human Peripheral T Cells Using Sendai Virus in Feeder-free Conditions

Recently, iPSCs have attracted attention as a new source of cells for regenerative therapies. Although the initial method for generating iPSCs relied on dermal fibroblasts obtained by invasive biopsy and retroviral genomic insertion of transgenes, there have been many efforts to avoid these disadvantages. Human peripheral T cells are a unique cell source for generating iPSCs. iPSCs derived from T cells contain rearrangements of the T cell receptor (TCR) genes and are a source of antigen-specific T cells. Additionally, T cell receptor rearrangement in the genome has the potential to label individual cell lines and distinguish between transplanted and donor cells. For safe clinical application of iPSCs, it is important to minimize the risk of exposing newly generated iPSCs to harmful agents. Although fetal bovine serum and feeder cells have been essential for pluripotent stem cell culture, it is preferable to remove them from the culture system to reduce the risk of unpredictable pathogenicity. To address this, we have established a protocol for generating iPSCs from human peripheral T cells using Sendai virus to reduce the risk of exposing iPSCs to undefined pathogens. Although handling Sendai virus requires equipment with the appropriate biosafety level, Sendai virus infects activated T cells without genome insertion, yet with high efficiency. In this protocol, we demonstrate the generation of iPSCs from human peripheral T cells in feeder-free conditions using a combination of activated T cell culture and Sendai virus.

Using this protocol, users are able to generate iPSCs from human peripheral T cells stably. iPSC generation from T cells with SeV and matrigel showed approximately 0.002% – 0.005% of efficiency of cell reprogramming in between several donor cases and SeV were not detected after several passages16. Figure 1A shows a schematic of the protocol for generating T cell-derived iPSCs in feeder-free conditions using matrigel and mTeSR medium. Around 20–30 days after infection with SeV, iPSC colonies are recognized by their ESC colony-like morphology (Figure 1B). Immunofluorescence staining revealed expression of typical pluripotent cell markers (NANOG, OCT3/4, SSEA4, TRA-1-60, and TRA-1-81) in T cell-derived iPSCs generated under feeder-free conditions (Figure 1C).
<img alt="Human T cell reprogramming to iPSCs; diagram and microscopy images of marker expression analysis." src="/files/ftp_upload/53225/53225fig1highres.jpg" width="700" data-altupdatedat="1787630408000" data-alt="Figure 1"> 
Figure 1. (A): A schematic of the protocol for reprogramming T cells under feeder-free conditions in this study. (B): A typical ESC-like iPSC colony on day 27 after blood sampling under feeder-free conditions. (C): ALP staining and immunofluorescence staining for pluripotency and surface markers (NANOG, OCT3/4, SSEA4, TRA-1-60, and TRA-1-81) in T cell-derived iPSCs generated under feeder-free conditions. <a href="https://www.jove.com/files/ftp_upload/53225/53225fig1highres.jpg" target="_blank">Please click here to view a larger version of this figure.</a>

This protocol describes how to generate induced pluripotent stem cells (iPSCs) from human peripheral T cells in feeder-free conditions using a combination of matrigel and Sendai virus vectors containing reprogramming factors.

Recently, iPSCs have attracted attention as a new source of cells for regenerative therapies. Although the initial method for generating iPSCs relied on ...

The overall goal of this procedure is to generate induced pluripotent stem cells or IPCs from human peripheral T cells in feeder free conditions. This method can help answer key questions in the field of regenerative medicine, including how IPS cells can be applied into clinical use. The main advantage of this technique is that IPS cells can be cured without the inclusion of possible harm refactor, which reduces the risk of pathogenicity.The implication of this technique extends world clinically relevant IPS cell-based therapies because of the, this invasive cell sampling combined with reduce risk of exposing the development IPS cells to undefined pathogens. So this method can provide insight into IPS service clinical therapy. It can also be applied to other areas such as disease modeling conditions.Begin preparing activated human T cells by diluting 10 milliliters of heparinized whole blood with 10 milliliters of DPBS pipette. 15 milliliters of fol solution into a 50 milliliter conical tube. Slowly pipette the diluted blood running along the inside wall of the tube to layer on top of the solution.Be careful not to disturb the interface. Centrifuge the tube at 400 times G for 30 minutes at room temperature. After centrifugation, observe three layers, including a lower clear layer, a thin white layer containing mononuclear cells and an upper milky plasma layer.Transfer the mononuclear cell layer to a new 50 milliliter conical tube without transferring any fit hole solution. Next, add DPBS to bring the total volume to 10 milliliters. Centrifuge the tube at 200 times G for five minutes at room temperature.Discard the supernatant, wash the cells with 10 milliliters of DPBS centrifuge the tube at 200 times G for five minutes and remove the supernatant. Then add one milliliter of KBM 5 0 2 medium to the cells and count using a hemo cytometer to prepare the cell culture dish coat the wells of a six well plate with 10 micrograms per milliliter of anti-human CD three antibody solution in PBS. Incubate the plate at 37 degrees Celsius and 5%carbon dioxide for at least 30 minutes.After incubation, remove the antibody solution from the plate eight and wash once with PBS seed the mononuclear cells at a density of 2.5 times 10 to the fifth cells per square centimeter in a total volume of two milliliters of KBM 5 0 2 medium in the coated six well plates incubate the cells for three to seven days without changing the medium, at which point the T-cell should reach con fluency following the three to seven days. Transfer the activated T-cells with a medium to a 15 milliliter conical tube and centrifuge at 200 times G for five minutes. Remove the SNAT and add one milliliter of fresh KBM 5 0 2 medium.Count the cells and plate 1.5 times 10 to the six cells in two milliliters of KBM 5 0 2 medium into each well of an anti CD three antibody coated six well plate next thaw the OC three SOX two, KLF four, and C-M-Y-C-H, and L sendi virus solutions on ice at each engineered Sendai virus individually to each well and a multiplicity of infection of 10. Incubate at 37 degrees Celsius and 5%carbon dioxide for 24 hours. Then collect the infected cells with a pipette and transfer them to a 15 milliliter conical tube.Centrifuge the cells at 200 times G for five minutes. Remove the supernatant and add two milliliters of fresh KBM 5 0 2 medium. Replace the cells in the wells of a six well plate and incubate for 24 hours in a cell culture incubator.To recede the cells first thaw the basement membrane matrix solution at four degrees Celsius overnight dissolve 0.2 milliliters of the thought solution in 10 milliliters of DMM F 12 medium plate five milliliters of the basement membrane matrix solution into 100 millimeter dishes. Leave the plates at room temperature for at least 30 minutes to allow the matrix to coat the dish before seeding cells. Meanwhile, collect the SAI virus infected T cells in a 15 liter conical tube and centrifuge at 200 times G for five minutes.Then resuspend the palate in one milliliter of fresh KBM 5 0 2 medium, and count the cells using a hemo cytometer after the 30 minute incubation period. Remove the basement membrane matrix solution from the two plates, then resuspend one times 10 to the fifth cells and separately one times 10 to the six cells into 10 milliliters of fresh M-T-E-S-R medium, a feeder cell free culture medium for ipsc. Pipette each cell suspension to a separate 100 millimeter plate.Incubate the plate in a cell culture incubator. Changing the medium every other day after 20 to 30 days. Colonies that resemble embryonic stem cell colonies should appear.Prepare six wall plates for IPSC expansion by incubating one milliliter of basement membrane matrix solution in each well for 30 minutes at room temperature. Meanwhile, view culture plates containing IPSC colonies under a stereo microscope and isolate individual colonies by scraping them with a 20 microliter pipette. Transfer each colony to a well and a 96 wall plate containing 20 microliters of M-T-E-S-R medium.After transferring the colonies, add 200 microliters of M-T-E-S-R medium to each well and pipette up and down to disrupt the colony. After removing the basement membrane matrix solution from the six well plates transfer cells from an individual colony to each well then add two milliliters of M-T-E-S-R medium, incubate the cells in a cell culture incubator and change the medium every other day using feeder free culture and serum free media ipsc were generated from human peripheral T cells. Immunofluorescent staining revealed expression of typical pluripotent cell markers, including nano T three four SSEA four, TRA one 60, and TRA 180 1.In these derived IPSE lines. While attempting this procedure, it's important to remember to perform all steps, taking into account all all the important sterility and bio safety considerations.

generation-induced-pluripotent-stem-cells-from-human-peripheral-t

Research

JoVE Journal

Developmental Biology

We demonstrate the protocol for the generation of induced pluripotent stem cells from human somatic cells using lentivirus-mediated delivery of the human factors Oct4, Sox2, Nanog, and Lin28.  Pluripotency was confirmed by morphology and the presence of embryonic stem (ES) cell-specific markers.

Generation of Induced Pluripotent Stem Cells by Reprogramming Human Fibroblasts with the Stemgent Human TF Lentivirus Set

Generating induced pluripotent stem cell (iPSC) lines produces lines of differing developmental potential even when they pass standard tests for pluripotency. Here we describe a protocol to produce mice derived entirely from iPSCs, which defines the iPSC lines as possessing full pluripotency1.

Generation of Mice Derived from Induced Pluripotent Stem Cells

Here we show a simple and effective protocol for the generation of human iPSCs from 3-4 ml of peripheral blood using a single lentiviral reprogramming vector. Reprogramming of readily available blood cells promises to accelerate the utilization of iPSC technology by making it accessible to a broader research community.

Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood Using the STEMCCA Lentiviral Vector

Here, we present our established method to reprogram human somatic cells into transgene-free human iPSCs with Sendai virus, which shows consistent outcome and enhanced efficiency.

Efficient Generation Human Induced Pluripotent Stem Cells from Human Somatic Cells with Sendai-virus

A method was developed to directly derive human neural stem cells from hematopoietic progenitor cells enriched from peripheral blood cells.

Direct Induction of Human Neural Stem Cells from Peripheral Blood Hematopoietic Progenitor Cells

Induced pluripotent stem cells (iPSCs) represent a source of patient-specific tissues for clinical applications and basic research. Here, we present a detailed protocol to reprogram human peripheral blood mononuclear cells (PBMNCs) obtained from frozen buffy coats into viral-free iPSCs using non-integrating episomal plasmids.

Generation of Induced Pluripotent Stem Cells from Frozen Buffy Coats using Non-integrating Episomal Plasmids

The goal of this protocol is to show the protocol for reprogramming melanoma tumor-infiltrating lymphocytes into induced pluripotent stem cells.

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

We propose a protocol for reprogramming peripheral blood mononuclear cells (PBMCs) into induced pluripotent stem cells (iPSCs). By plating the transduced blood cells onto matrix-coated plates with centrifugation, iPSCs are successfully induced from floating cells. This technique suggests a simple and effective reprogramming protocol for cells such as PBMCs and CBMCs.

Induced Pluripotent Stem Cell Generation from Blood Cells Using Sendai Virus and Centrifugation

This protocol describes a detailed method for efficient generation of integration-free iPSCs from human adult peripheral blood cells. With the use of four oriP/EBNA-based episomal vectors to express the reprogramming factors, KLF4, MYC, BCL-XL, or OCT4 and SOX2, thousands of iPSC colonies can be obtained from 1 mL of peripheral blood.

Generation of Integration-free Induced Pluripotent Stem Cells from Human Peripheral Blood Mononuclear Cells Using Episomal Vectors

This article describes a procedure to produce iTenocytes by generating iPSC-derived mesenchymal stromal cells with combined overexpression of Scleraxis using a lentiviral vector and uniaxial stretching via a 2D bioreactor.

Generation of Induced Pluripotent Stem Cell-Derived iTenocytes via Combined Scleraxis Overexpression and 2D Uniaxial Tension

Learn to generate induced pluripotent stem cells from human peripheral T cells using Sendai virus vectors in feeder-free conditions. This method enables safe clinical applications in regenerative medicine.

Generation of Induced Pluripotent Stem Cells from Human Peripheral T Cells Using Sendai Virus in Feeder-free Conditions

Explore More Videos